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Summary
Tumor necrosis factor (TNF) released by lipopolysaccharide (LPS)-stimulated mononuclear phago-
cytes is a critical mediator of sepsis. We examined the capacities of rough mutant Salmonella
typhimurium LPS (Rc) and LPS partial structures lipid A, monophosphoryl lipid A (MPLA),
lipid IVY, and lipid X to induce production of TNF in whole blood. Rc LPS (0.0001-10 ng/ml)
produced a dose-dependent release ofTNF as determinedby cytotoxicity ofactinomycin D-sensitized
L929 murine fibroblasts. Lipid A, MPLA, lipid IVe, and lipid X exhibited decreasing capacities
to stimulate production of TNF in whole blood, respectively. Fractional dearylation of LPS by
incubation with acyloxyacyl hydrolase isolated from human leukocytes produced a reduction in
the capacity ofLPS to induce TNF release in whole blood. Maximal enzymatic dearylation reduced
activity of LPS by >100-fold.
Coincubation with lipid IVY inhibited TNF release induced by Rc LPS or lipid A, but not
by phorbol ester. In contrast, MPLA, lipid X, and deacylated LPS failed to inhibit LPS-stimulated
release of TNF. Corresponding to the inhibition of the release of TNF protein, lipid IVn also
inhibited the accumulation of TNF mRNA in LPS-stimulated mononuclear cells. These results
suggest that lipid IVY may act as a competitive antagonist of LPS, perhaps at the receptor level.
Gram-negative bacterial infection induces a complex array
of inflammatory responses including fever, leu ocytosis,
and activation of the coagulation, complement, and kinin
systems. These manifestations ofGram-negative infection are
primarily induced by heat-stable endotmins released from the
outer membrane ofGram-negative bacteria. LPS are the prin-
cipal biologically active component of endotoxins that have
a common macromolecular architecture. Threemajor domains
comprise LPS structure: an 0-antigen side chain composed
of repeating oligosaccharides, a core polysaccharide, and
lipid A.
Chemical degradation studies and bacterial mutants with
defective synthesis of LPS have provided insights into bio-
synthesis and structure-function relationships of LPS and its
components. Lipid A is the smallest substructure of LPS ex-
hibiting all biological activities (1). Lipid A from common
pathogens exhibit the same general features, a 0-1,6 D-glu-
cosamine disaccharide backbone, with four mole equivalents
of 3-hydroxymyristate or 3-hydroxylaurate in amide and ester
linkage, and two monophosphate groups at 1 and 4: Aryl
residues are located at the 2, 2, 3, and 3' positions on the
disaccharides, and the R-3 hydroxyl substitutes of the aryl
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residues are further esterified with laurate and myristate,
forming acyloxyacyl groups. Escherichia coli K12 lipid A has
2' and 3' acyloxyacyl groups, compared with Salmonella min-
nesota, which may have acyloxyacyl moieties at 2, 2, and 3:
The biosynthesis of lipidA involves the formation of acyl-
ated monosaccharide precursors that are generated from UDP
N-acetylglucosamine (2). Two early intermediates are UDP-
2,3-diacylglucosamine and 2,3-diacylglucosamine 1-phosphate
(lipid X), which condense to form a tetraacyldisaccharide
1-phosphate with the characteristic ß-1,6 linkage (3, 4). The
latter metabolite is then phosphorylated at position 4' to
generate lipid IVY (5) (Fig. 1) . Large amounts of lipid IVY
can be isolated from mutants defective in the biosynthesis
of 3-deoxy-D-manno-octulosonic acid (6).
Further evaluation of the structurally active components
of LPS has come from purification of neutrophil acyloxyacyl
hydrolase. This enzyme selectively cleaves the acyloxyacyl bonds
found in LPS (7, 8). Hydrolysis of Rc LPS yields a partial-
deacylated LPS that displays markedly reduced reactivity in
the dermal Shwartzman reaction (9) and fails to stimulate
endothelial cells to express proadhesive activity for neutro-
phils (10), but remains a potent B cell mitogen (9, 10). These
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phosphorylated disaccharide is theminimalstructure exhibiting
full LPS activity.
LPS exerts much of its activity through thegeneration of
cytokines. TNF-a/cachectin is amonokine released in response
to LPS stimulation of mononuclear phagocytes. Data from
several studies demonstrate that it is a critical mediator of
septic shock (16-19). Recently, we have reported a method
for evaluating theex vivo production of TNF in wholeblood,
therelevant physiologic milieu (20). In this report, we further
investigate the ability ofLPS and related structures to stimu-
late production of TNF in whole blood ex vivo. We report
that deacylated LPS, monophosphoryl lipid A (MPLA)t,
lipid IVA, and lipid X all show markedly decreased ability
to stimulateTNFproduction compared with Rc LPSor lipid
A. Lipid IVA and lipid X are significantly less active than
MPLA and deacylated LPS. Most importantly, lipid IVA,
but not MPLA or lipid X, inhibits the release of TNF pro-
tein and the accumulation ofTNF mRNA induced by lipid
A or Rc LPS.
Materials and Methods
Reagents.
￿
Deacylated LPS preparations were prepared as previ-
ouslydescribed (7, 8, 21). Briefly, S. typhimurium Rc LPS was in-
cubated in a reaction mixture (20 mM Tris citrate, pH 4.8, 150
mM NaCl, 1 mg/ml BSA, 5 mM CaC12, 0.5% Triton X-100)
with and without human neutrophil acyloxyacyl hydrolase. Con-
stant amountsof acyloxyacyl hydrolaseandLPS(maintaining acon-
stantratio) were incubated for varyingtimes, up to 72 h for max-
imal deacylation (removal of 31-33% of the 3H-labeled fatty acids
from the LPS [9]). The mixtures were then treated with 2 vol of
chilled ethanol, precipitating theLPS and BSA, which were then
washed once with 80% ethanol. The precipitates were suspended
in pyrogen-free saline and stored at -70°C until used.
MPLA (byacid hydrolysis ofS. minnesota R595) and diphospho-
ryl lipidA(by hydrolysis at pH 4.5 from E. coli K12,D31m4) were
obtained from List Biological Laboratories, Inc. (Campbell, CA)
and suspended in 0.5% triethylamine-PBS. Lipid X was the gift
of Dr. Ingolf Macher, Sandoz Forschungsinstitut (Vienna, Aus-
tria), and was suspended in 0.5% triethylamine-PBS with sonica-
tion. Lipid IVA was isolated from S. typhimurium, purified as pre-
viously described (6), and suspended with sonication in 0.5%
triethylamine-PBS. Humanrecombinant TNF-a(rhTNF)and poly-
clonal antibody to TNF-at were gifts of Genentech, Inc. (San Fran-
cisco, CA). PMAwasobtained from SigmaChemical Co. (St. Louis,
MO).
Production of TNF in Whole Blood Ex Viva
￿
Blood was drawn
into polypropylene syringes containing heparin (10U/ml finalcon-
centration). Heparinized wholebloodwas pipetted into 5-ml poly-
propyleneFalcon tubes (Becton Dickinson& Co., Mountain View,
CA) in 225-F,1 aliquots. Test reagents were diluted in PBS to ap-
propriate concentrations, and 25 pl of the reagent was added per
aliquot of wholeblood andgently vortexed. Themixturewas then
incubated at 37°C with constant gentle agitation. After incuba-
tion 750 itl of RPMI medium (<0.03 EU/ml; MA Bioproducts,
Walkersville, MD) was added, andthecellular componentwaspelleted
' Abbreviations used in this paper: MPLA, monophosphoryl lipid A;
rhTNF, recombinant human TNF-a.
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by centrifugation at 800 g for 15 min. The diluted plasma was re-
moved for assay of TNF.
L929 Cytotazicity Assay.
￿
L929 murine fibroblasts (ATCC CCLI;
American Type Culture Collection, Rockville, MD) were grown in
75-cm2flasks in RPMI 1640 with 10% horse serum (Flowlabora-
tories, Inc., Mclean, VA). Cells were detached by trypsin, resus-
pended in growth medium, plated in 96-wellflat-bottomedplates
(Costar, Cambridge, MA) at 2.5 x 105 cells/well, and grown to
confluence at 37°C in 5% C02. 50 pl of actinomycin D (4
P.g/ml) in RPMI medium containing 5% newborn calf serum
(Gibco Laboratories, Grand Island, NY) was added to each well
at the time of assay. The test supernatants were addedto quadru-
plicate wells (final volume per well, 200 P1). Control wells were
treated with RPMI medium containing 5% newborn calf serum.
Maximum cytotoxicity wasdeterminedby addition ofrhTNF (100
U/ml). After incubation overnight at 37°C, plates were washed
three times with PBS with 2% newborn calf serum. Remaining
cells were fixed and stained with crystal violet in 20% methanol
for 20 min, andthen washed with water to remove unbounddye.
Stained cells were then lysed with 0.1 M sodium citrate, pH 4.2,
in 50% ethanol, and plates were read in a Titertek Multiscan
MCC/340 microplate reader (Flow Diagnostics, McLean, VA) at
an absorbance of 570 nm (As,o). Cytotoxicity was calculated by
the following: ratiocytotoxicity = (A57ocontrol - As7o TNF) -
(As7o test - A57o TNF)/(A57o control - As,o TNF), where A57o
controlis theabsorbance ofwells incubatedwith RPMI/5% sera,
A5,o TNF is absorbance wells incubated 100 U/ml rhTNF, and
A5,o Test is the absorbance of wells incubated with the plasma su-
pernatantfrom whole blood assay. 1 U of TNFwas defined as the
amount producing 50% cytotoxicity in the L929 assay.
Northern Blot Analysis.
￿
Aliquots of heparinized wholeblood
were incubated for 4 h at 37°C with sterile saline alone or saline
containing Re LPS (10 ng/ml finalconcentration), lipid IVA (1,000
ng/ml final concentration), or both Re LPS and lipid IVA. At the
endof theincubation, actinomycin Dwas then added to finalcon-
centration of 20,ug/ml to inhibit further RNA synthesis during
subsequent processing. Mononuclear cells were isolated from the
wholeblood by Ficoll-Hypaque (Pharmacia Fine Chemicals, Pis-
cataway, NJ) density centrifugation with PBS buffer. The mono-
nuclear cell layer waspelleted at 800g for 15 min. RNA was ex-
tracted using apreviously describedmethod (21). Briefly, the cell
pellet was solubilized in a solution of 5.7 M guanidinehydrochlo-
ride and 0.1 M potassium acetate, pH 5.0, and sonicated. A half-
volume of 100% ethanol was added and incubated overnight at
-30°C. Theprecipitate waspelletedby centrifugation at 12,000 g
for20 minat 4°C, andresuspended in solution of5.4 M guanidine
hydrochloride, 0.1 Mpotassiumacetate, pH 5.0, and0.025 MEDTA,
pH 8.0.DNAwas sheared by agitation through a22-gauge needle
and precipitated at -30°C. Final resuspension was in 0.1 M so-
dium chloride, 0.01M EDTA, 0.2% SDS, and 0.02 MTris-hydro-
chloride, pH 8.0. RNA was extracted twice with equal volumes
(0.5 ml)ofphenol-chloroform-isoamyl alcohol, then in chloroform-
isoamylalcohol, and precipitated with 100% ethanol. Theprecipi-
tated RNA (10 NAg/lane) was separated by a formaldehyde 1.2%
agarose gel and transblotted to nitrocellulose by capillary transfer
overnight. The baked blots were prehybridized and then hybrid-
ized initially with embryonic chick brain actin cDNA (pAl-pst;
2-kb fragment) to document equal transfer of RNA. They were
then stripped and rehybridized with a TNF cDNA probe (a gift
of Dr. H. M. Shepard, Genetech, Inc.) and labeled with "P by
multiprime DNAlabeling (Amersham Corp., Arlington Heights,
IL). Blots were washed and autoradiographs were quantitated by
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￿
Structures of lipid X, lipid IVA, and E. coli lipid A .
Lipid X (2,3-diacylglucosamine 1-phosphate), an early precursor, con-
denses with UDP-2,3-diacylglucosamine and is phosphorylated at the
4' position forming lipid IVA. Addition of 6' oligosaccharide core res-
idues, and esterification of laurate or myristate at 2' and 3' positions
to form acyloxyacyl groups, yields Rc LPS. Salmonella lipid A may be
additionally substituted at position 2' to form three acyloxyacyl
groups.
laser densitometry (UltrascanXL; LKB Instruments, Inc., Gaithers-
burg, MD) .
Results
LPS Induces Production ofTNF in a Dose-dependent Manner.
Addition ofRc LPS (0.0001-10 ng/ml) to whole bloodresulted
in dose-dependent production of an activity in the diluted
plasma that was cytotoxic for actinomycin D-treated L929
murine fibroblasts (Fig. 2). To determine whether the cyto-
toxic activity was TNF, aliquots of whole blood were stimu-
latedwith Rc LPS (0.05 ng/ml) for 6 h, and the diluted plasmas
were then incubated for 12 h with RPMI medium, nonspecific
rabbit IgG, or polyclonal rabbit antisera to TNF. The poly-
clonal antibody to TNF abrogated cytotoxic activity (cyto-
toxicity ratio: RPMI, 0.737 t 0.042; nonspecific IgG, 0.699
t 0.041; antiTNF IgG, 0 t 0.002; means t SEM of six
experiments).
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Figure 2.
￿
Rc LPS (O) and dearylated Rc LPS (") induce dose-
dependent production of TNF in whole blood. Whole blood was in-
cubated with RPMI medium or RPMI medium containing serial di-
lutions of Rc LPS or dearylated LPS (0.0001-100 ng/ml final concen-
tration) for 4 h at 37°C. After incubation, the sample was diluted
1 :3 with RPMI medium and centrifuged. The supernatant plasma
was assayed for TNF. Values represent the means t SEM of quadru-
plicate wells in 10 experiments.
Deacylation ofLPS Reduces Activity.
￿
The ability of dea-
cylated LPS to stimulate production of TNF in whole blood
ex vivo TNF was diminished compared with Rc LPS (Fig.
2). Greater than a 100-fold increase (wt/wt) of maximally
dearylated LPS relative to Rc LPS was required to induce an
equivalent production ofTNF. The concentration ofLPS re-
quired to generate 1 U of TNF (50% cytotoxicity for L929
cells) was 0.022 t 0.005 ng/ml Rc LPS vs. 3.60 t 1.18 ng/ml
of dearylated LPS (means t SEM of seven experiments,
p < 0.05). Fractional deacylation of LPS produced by graded
exposure of LPS to the leukocyte acyloxyacyl hydrolase pro-
duced a corresponding graded decrease in the capacity of the
LPS to induce TNF production (Fig. 3).
Lipid A Precursors and Analogues Exhibit Reduced Activity.
Lipid A, MPLA, lipid IVA, and lipid X exhibited decreasing
capacity to stimulate production ofTNF in whole bloodcom-
pared with Rc LPS and Re LPS (Fig. 4 and Table 1). Re
LPS was essentially identical to Rc LPS (50% cytotoxicity,
0.037 vs. 0.022 ng/ml) . Lipid A was more active than dea-
cylated LPS (50% cytotoxicity, 0.47 vs. 3.60 ng/ml), but
demonstrated only one-tenth the activity of Rc LPS. MPLA
and lipid IVA were both markedly less active than Rc LPS
and dearylated LPS. Significant cytotoxicity was not observed
until the concentration of MPLA was at least 500 ng/ml,
and lipid IVA was 1,000 ng/ml. The capacity of lipid IVA
to induce cytotoxicity at 1,000 ng/ml was variable, with a
range of 0.0-0.745 ratio cytotoxicity in 16 separate experi-
ments. In 7 of 16 experiments, a lipid IVA concentration of
1,000 ng/ml induced no release of TNF. Lipid X was virtu-
ally inactive.
Lipid IVA Inhibits LPS
￿
The dose-dependent production
of TNF in whole blood by Rc LPS or lipid A was decreased
by coincubation with lipid IVA (Fig. 5). Complete inhibi-
tion was observed at a ratio of lipid IVA to LPS or lipid A
(wt/wt) >100 :1 and 50:1, respectively. Deacylated LPS,u ~X a
O
U
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Figure 3.
￿
Fractional deacylation of Rc LPS produces a correspond-
ing reduction in the capacity of LPS to stimulate production of TNF.
Rc LPS was incubated with acyloxyacyl hydrolase under graded time
exposure to produce fractional deacylation of LPS. In this preparation,
removal of 31.7% of 3H-labeled fatty acids represented cleavage of
>90% of the acyloxyacyl bonds. Dilutions of de;,cylated LPS prepara-
tions in RPMI medium were incubated with whole blood for 4 h at
37°C. After incubation, the samples were diluted 1:3 with RPMI
medium and the supernatant plasmas assayed for TNF. Values are the
means ± SEM of three separate experiments.
MPLA, and lipid X failed to inhibit production of TNF by
LPS at ratios up to 1,000:1 (Table 2). Maximal inhibition
was observed with simultaneous addition of lipid IVA and
LPS. Addition of lipid IVA 2 h after addition of LPS or lipid
Afailed to inhibit stimulationof TNF production, with an
increasing inhibition as the time interval between additions
was shortened. At a ratioof 100:1 (wt/wt), addition oflipid
IVA to whole blood simultaneously with LPS produced 91.6
± 12.9% inhibition, 15 min afterLPS 39.0 ± 20.6% inhi-
bition, 30 min after 15.5 ± 6.4% inhibition, 60 min after
LPS 6.0 ± 1.3% inhibition, and 2 h after LPS 1.4 ± 1.3%
0.001 0.01 0.1 1 .0 10 100 1000
Concentration LPS (ng/mi)
Figure 4.
￿
LPS substructures exhibit reduced capacity to induce re-
lease of TNF. Serial dilutions of Rc LPS IT) and substructures Re
LPS (), deacylated LPS (t), lipid A ("), MPLA (A), lipid IVA (A),
and lipid X (0) were incubated in whole blood for 4 h at 37°C. Af-
ter incubation, the samples were diluted 1:3 with RPMI medium,
centrifuged, and the resultant supernatant plasma was assayed for
TNF. Values represent means ± SEM of four or more experiments.
Asterisks indicate the lowest concentration of MPLA, lipid IVA, and
lipid X producing significant cytotoxicity (p < 0.005 by paired t test).
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RPMI medium containing serial dilutions of Rc LPS, Re LPS, de-
acylated LPS, lipid A, lipid IVA, or lipid X was added to whole
blood. After a 6-h incubation at 37°C, samples were diluted 1:3
with RPMI medium. The diluted plasma was collected by centrifu-
gation and assayed for TNF activity by direct cytotoxicity of ac-
tinomycin D-sensitized L929 cells. Data from at least four separate
experiments were averaged for calculation of cytotoxicity at each di-
lution. The concentration of LPS structure producing 50% cytotox-
icity (1 U TNF) was determined by regression analysis of the linear
portion of the averaged dose-response curve.
inhibition (mean percent inhibition t SEM for three ex-
periments).
PMA (10-100ng/ml) induced dose-dependent production
ofTNF in whole blood as determined by L929 cytotoxicity
(cytotoxicity ratio at 1 ng/ml, 0.021 ± 0.032; 10 ng/ml,
0.276 ± 0.204;100 ng/ml, 0.537 ± 0.239; and 1,000 ng/ml,
100
~O
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￿
Lipid IVA inhibits stimulation of TNF production by Rc
LPS and lipid A. Whole blood was coincubated with lipid IVA
(1-100 ng/ml) and Rc LPS (") (0.05-0.1 ng/ml), or lipid A (O)
(0.1-1.0 ng/ml), for 4 h. After incubation, the samples were diluted
with RPMI medium 1:3, centrifuged, and the supernatant plasmas
assayed for TNF. Percent inhibition was calculated as: cytotoxicity
(LPS) - cytotoxicity (LPS + lipid IVA)/cytotoxicity (LPS). Values
represent means ± SEM of six experiments.
Table 1. Comparison of LPS Stnsctures
Concentration producing
Deacylation LPS structure 50% cytotoxicity
o2.2%
010.0%
e14.2 % ng/ml
" 24.0 %
a29.0% Rc LPS 0.022
m31.7% Re LPS 0.037
Lipid A 0.405
Deacylated 3.60
MPLA 454.4
Lipid IVA 2,656
Lipid X >5,000Table 2.
￿
Effect of Partial Structures on LPS-stimulated
Production of TNF
Coincubation
￿
Percent inhibition
Lipid IVA
￿
97.2 ± 3.2
Deacylated LPS
￿
0.75 ± 2.8
MPLA
￿
4.8 ± 5.6
Lipid X
￿
0 ± 0
Whole blood was incubated for 6 h at 37°C with Rc LPS (0.01-
1 ng/ml) alone or with partial structures and Rc LPS at a ratio
100 :1 . The concentrations were lipid IVA , 100 ng/ml ; deacylated
LPS, 1 ng/ml ; MPLA, 10 ng/ml; and lipid X, 100 ng/ml . After
incubation, the sample was diluted 1:3 with RPMI medium, cen-
trifuged, and the supernatant diluted plasma assayed for TNF by
direct cytotoxicity of actinomycin D-sensitized L929 cells . Percent
inhibition was calculated as : 100 x (cytotoxicity Rc LPS -
cytotoxicity Rc LPS and precursor)/cytotoxicity with Rc LPS .
Values represent the mean ± SEM of four experiments .
0.511 ± 0.219; means ± SEM ofthree experiments) . Equiva-
lent dilutions ofPMA in RPMI failed to induce cytotoxicity
in the L929 assay (data not shown) . Lipid IVA at ratios up
to 10:1 (wt/wt) failed to inhibit stimulation of production
ofTNF byPMA in whole blood. The cytotoxicity ratio after
incubation with PMA alone (10 ng/ml) was 0.276 ± 0.204
vs. 0.445 ± 0.321 when coincubated with lipid IVA (100
ng/ml ; means ± SEM of four experiments) . Trials ofinhibi-
tory ratios >10:1 were prohibited by lack of significant
production ofTNF stimulation at PMA concentrations <10
ng/ml, and the slight stimulation by lipid IVA at concen-
trations >100 ng/ml .
Lipid IVA Inhibits Induction of TNF mRNA by LPs .
Messenger RNA for TNF was not detected in whole blood
incubated with RPMI medium alone. Incubation with Rc
LPS (10 ng/ml) induced accumulation ofTNFmRNA that
was inhibited by coincubation with lipid IVA (1,000 ng/ml)
(Fig. 6) . Corresponding production ofTNF protein was de-
termined by L929 assay; cytotoxicity ratio withRPMImedium
alone was 0.0 ± 0.0 ; Rc LPS, 0.913 ± 0.017 ; lipid IVA,
0.002 ± 0.005 ; and Rc LPS/lipid IVA, 0.191 ± 0.057
(average of quadruplicate wells ± SEM for corresponding
experiment) . Similar results were obtained in three separate
experiments comparing accumulation of TNFmRNA and
production of TNF protein .
Discussion
TNF released by LPS-stimulated mononuclear phagocytes is
a critical mediator of septic shock (16-19) . Recently, we
reported a physiologically relevant method ofevaluating the
production ofTNF in whole blood ex vivo (20) . In this re-
port, we investigate the structure-function relationships of
LPS and its components in the stimulation ofTNF release
in whole blood .
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Figure 6 .
￿
Lipid IVA inhibits induction of TNF mRNA by LPS .
Heparinized whole blood was incubated 4 h at 37°C with sterile sa-
line alone (lane 1), saline containing Re LPS (10 ng/ml) (lane 2),
lipid IVA (1,000 ng/ml) (lane 4), or both Re LPS and lipid IVA (lane
3) . After incubation, actinomycin D (20 Icg/ml) was added to inhibit
RNA synthesis during subsequent isolation of the mononuclear cells .
RNA was extracted from isolated mononuclear cells as described in
Materials and Methods. Total cellular RNA (10 kg/lane) was hybrid-
ized to 32P-labeled TNF cDNA or to "P-labeled chicken /3-actin
cDNA probe. Ratios of TNF to actin were determined by peak ab-
sorbance (AU) of TNF and actin, as measured by laser densitometry.
Rc and Re LPS were potent inducers ofTNF release in
whole blood . Production ofTNF, as determined by cytotox-
icity of actinomycin D-sensitized L929 murine fibroblasts,
was detectable at concentrations of Rc LPS as low as 5-10
pg/ml. Although lipid A was active in inducing production
ofTNF, it was not as potent as Rc or Re LPS . Re LPS has
been demonstrated to possess enhanced activity in pyroge-
nicity, Schwartzman reaction, and mitogenicity, but does not
exhibit increased lethality over synthetic and natural lipid A
preparations (22) .
The LPS substructures, MPLA, lipid IVA, and lipid X,demonstrated decreasing capacity to induce production of
TNF. At the doses of lipid IVA and lipid X required to in-
duce significant cytotoxicity in the L929 assay (1-10 wg/ml),
contamination with trace amounts ofLPS remains a possible
confounding issue. Less than 0.001% contamination with LPS
would be-sufficient to provoke release of TNF in the whole
blood assay. Both precursors may therefore be even less active
than demonstrated. In contrast to their markedly reduced ac-
tivity in the human whole blood assay, both lipid IVA and
lipid X have been reported to stimulate murine B cell prolifer-
ation (23, 24), and to activate the Limulus clotting system
(25, 26).
Similar to previous reports ofreduced activity in the dermal
Shwartzman reaction (9) and in stimulation of endothelial
proadhesive activity for neutrophils (10), deacylated LPS was
markedly less active than Rc LPS in stimulating TNF release
in whole blood. There was a >100-fold decrease (wt/wt) in
the ability of deacylated LPS to induce production of TNF
compared with properly acylated LPS (Rc). The markedly
reduced activity of lipid IVA compared with lipid A, its
properly acylated counterpart, further supports the impor-
tance of the acyloxyacyl groups for full induction of TNF
production in humancells. In addition, the synthetic analogues
of lipid IVA (compound 406, LA-14-PP) are only weakly
pyrogenic, have reduced capacity to elicit leukopenia in rabbits,
and are less active in provoking the local Shwartzman reac-
tion compared with a synthetic counterpart (LA-15-PP) of
lipid A (11, 27, 28) . Induction of IIA productionby human
monocytes by synthetic lipid A is also abrogated by removal
of the acyloxyacyl residues (29). However, lipid IVA is equi-
potent with lipidA in inducing murine lymphoma K L chain
synthesis (23), and synthetic lipid IVA analogues are equi-
potent in activating the Limulus clotting system (26), and
provoking lethality in galactosamine-primed mice (11, 27),
compared with the synthetic analogue oflipid A. These ob-
servations suggest that induction of cytokine production by
LPS involves a pathway of activation that requires proper acy-
lation of the LPS backbone, whereas stimulation of other
endotoxic activities (activation ofmurine lymphoma cells or
the Limulus clotting system) occurs by pathways that are less
sensitive to acylation of lipid A or synthetic analogues.
The significant reduction in the activity of MPLA (pre-
paredby mild hydrolysis ofLPS) compared with lipidA also
suggests an important role for the 1' phosphate, the only struc-
tural difference between MPLA and lipid A. This supports
prior studies in which synthetic analogues of lipid A (LA-
17-PP, LA-18-PP) and their monophosphate analogues were
active in activating the complement cascade and stimulating
the Limulus clotting system, but the monophosphate ana-
logues were inactive in inducing lethality of galactosamine-
loaded mice or the production of a serum factor in BCG-
primed mice cytocidal to L929 cells (28). The 6' position is
the site of attachment of the underlying disaccharide back-
bone that forms the core. The possible importance of the
core is suggested by the decreased activity of lipid IVA and
lipid A, which lack the KDO groups, compared with their
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analogous structures, deacylated LPS, and Rc LPS, which re-
tain a core oligosaccharide.
There are, however, alternative explanations, for these results.
Because the tetraacyldisaccharide backbone is hydrophobic,
loss of a phosphate group diminishes the solubility of lipid
IVA and lipid A. Despite suspension in 0.5% triethylamine
with sonication, decreased solubility may contribute to the
decrease in activity. In addition, residual acyloxyacyl groups
not removed by acyloxyacyl hydrolase during productionand
purification ofdeacylated LPS could increase the apparent ac-
tivity of deacylated LPS compared with lipid IVA. A single
acyloxyacyl group confers activity in the dermal Shwartzman
reaction (30, 31) and pyrogenicity in rabbits (26) .
Of particular interest was our finding that lipid IVA in-
hibited production of TNF from human cells by both Rc
LPS and lipid A. Lipid IVA (or precursor la [31, 32]) has
also recently been shown to inhibit induction of IM by LPS
or lipid A in human monocytes (32). In contrast, deacylated
LPS, MPLA, and lipidX failed to inhibit production of TNF
stimulation by Rc LPS or lipid A. Lipid X, however, has
been reported to impart partial protection against a lethal
dose ofendotoxin administered to mice (33). DeacylatedLPS
has previously been shown to inhibit the induction of en-
dothelial proadhesive activity for neutrophils by LPS (10),
whereas MPLA and lipid X failed to inhibit LPS-stimulated
endothelial proadhesiveness under the same conditions. We
were unable, however, to produce significant inhibition with
deacylated LPS in the whole blood assay. The lack ofinhibi-
tion by deacylated LPS may again reflect the extreme sensi-
tivity of the whole blood assay to LPS and the possible con-
tamination of the deacylated LPS preparation with residual
Rc LPS or incompletely deacylated LPS.
Northern blotting studies demonstrated that the inhibi-
tion of LPS-stimulated TNF production by lipid IVA was
associated with diminished accumulation of TNF mRNA.
Lipid IVA could prevent accumulation of the TNP mRNA
by pretranscriptional mechanisms (inhibition ofsignal trans-
duction), by inhibiting transcription, or by promoting degra-
dation of transcripts. The failure of lipid IVA to inhibit TNF
production in response to PMA, however, argues against a
nonspecific effect on transcriptional or post-transcriptional
mechanisms of regulation.
Although these studies do not delineate the precise mech-
anism by which lipid IVA inhibits leukocyte activation by
LPS, the results are consistent with lipid IVA acting as a
competitive antagonist of LPS binding to a receptor mole-
cule. An LPS-binding protein of 80 kD has been identified
in murine splenocytes (34), although it is not yet known
whether this protein is involved in signal transduction. 32p-
lipid IVA has also been used as a probe to detect specific
binding on the surface of macrophage tumor cells (35). Al-
ternatively, lipid IVA could prevent binding of LPS to a
plasma protein necessary for interaction with monocytes.
Serum is required for endotoxin binding to human mono-
cytes (36), and an LPS-binding protein has been identified
in mouse serum (37). Recently, an acute phaseserum protein
Lipid IV Inhibits Lipopolysaccharide-induced 'Iiimor Necrosis Factorhas also been described in humans, rabbits, mice, and rats
that binds a variety of LPS types, including Re LPS, dea-
cylated LPS, lipid A, and lipid IVA (38, 39).
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